IL6 and hyperlipidemia: Furthermore, DT administration to VSMCs derived from SM22α-DTR mice causes release of IL-6, MCP-1 and GM-CSF in culture, and in the presence of hyperlipidemia, increases serum levels of TNF-α and IL-6 in vivo [37].